blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2340841

EP2340841 - OSTEOGENESIS PROMOTER COMPRISING [4-(METHYLTHIO)PHENYLTHIO]METHANEBISPHOSPHONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.09.2017
Database last updated on 07.12.2024
Most recent event   Tooltip06.03.2020Lapse of the patent in a contracting state
New state(s): TR		published on 08.04.2020  [2020/15]
Applicant(s)For all designated states
Tohoku University
2-1-1, Katahira Aoba-ku Sendai-shi
Miyagi 980-8577 / JP
For all designated states
Showa University
1-5-8 Hatanodai Shinagawa-ku
Tokyo, 1428555 / JP
[2011/27]
Inventor(s)01 / SHINODA, Hisashi
c/o TOHOKU UNIVERSITY
2-1-1 Katahira
Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
02 / IGARASHI, Kaoru
c/o TOHOKU UNIVERSITY
2-1-1 Katahira
Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
03 / MURAKAMI, shinobu
c/o TOHOKU UNIVERSITY
2-1-1 Katahira
Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
04 / SUZUKI, Keiko
c/o SHOWA UNIVERSITY
1-5-8 Hatanodai
Shinagawa-ku
Tokyo 142-8555 / JP
 [2016/45]
Former [2011/27]01 / SHINODA, Hisashi
c/o TOHOKU UNIVERSITY 2-1-1 Katahira Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
02 / IGARASHI, Kaoru
c/o TOHOKU UNIVERSITY 2-1-1 Katahira Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
03 / MURAKAMI, shinobu
c/o TOHOKU UNIVERSITY 2-1-1 Katahira Aoba-ku
Sendai-shi Miyagi 980-8577 / JP
04 / SUZUKI, Keiko
c/o SHOWA UNIVERSITY 1-5-8 Hatanodai Shinagawa-ku
Tokyo 142-8555 / JP
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2016/45]Woods, Geoffrey Corlett
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2011/27]Woods, Geoffrey Corlett
J.A. Kemp & Co. 14 South Square Gray's Inn London
WC1R 5JJ / GB
Application number, filing date09811231.105.08.2009
[2011/27]
WO2009JP03758
Priority number, dateJP2008022548403.09.2008         Original published format: JP 2008225484
[2011/27]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010026701
Date:11.03.2010
Language:JA
[2010/10]
Type: A1 Application with search report 
No.:EP2340841
Date:06.07.2011
Language:EN
[2011/27]
Type: B1 Patent specification 
No.:EP2340841
Date:09.11.2016
Language:EN
[2016/45]
Search report(s)International search report - published on:JP11.03.2010
(Supplementary) European search report - dispatched on:EP29.02.2012
ClassificationIPC:A61K31/663, A61K9/08, A61K47/02, A61P1/02, A61P19/08, A61P43/00
[2011/27]
CPC:
A61K31/663 (EP,US); A61P1/02 (EP); A61P15/00 (EP);
A61P19/08 (EP); A61P43/00 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2016/45]
Former [2011/27]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
Extension statesALNot yet paid
BANot yet paid
RSNot yet paid
TitleGerman:OSTEOGENESEPROMOTER MIT [4-(METHYLTHIO)PHENYLTHIO]METHANBISPHOSPHONSÄURE ODER PHARMAZEUTISCH AKZEPTABLEM SALZ DARAUS ALS WIRKSTOFF[2011/27]
English:OSTEOGENESIS PROMOTER COMPRISING [4-(METHYLTHIO)PHENYLTHIO]METHANEBISPHOSPHONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT[2011/27]
French:PROMOTEUR D'OSTÉOGENÈSE COMPRENANT L'ACIDE [4-(MÉTHYLTHIO)PHÉNYLTHIO]MÉTHANEBISPHOSPHONIQUE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI EN TANT QU'INGRÉDIENT ACTIF[2011/27]
Entry into regional phase31.03.2011Translation filed 
31.03.2011National basic fee paid 
31.03.2011Search fee paid 
31.03.2011Designation fee(s) paid 
31.03.2011Examination fee paid 
Examination procedure31.03.2011Examination requested  [2011/27]
28.09.2012Amendment by applicant (claims and/or description)
12.12.2013Despatch of a communication from the examining division (Time limit: M04)
20.03.2014Reply to a communication from the examining division
01.06.2016Communication of intention to grant the patent
27.09.2016Fee for grant paid
27.09.2016Fee for publishing/printing paid
27.09.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  12.12.2013
Opposition(s)10.08.2017No opposition filed within time limit [2017/42]
Fees paidRenewal fee
11.08.2011Renewal fee patent year 03
10.08.2012Renewal fee patent year 04
19.08.2013Renewal fee patent year 05
13.08.2014Renewal fee patent year 06
10.08.2015Renewal fee patent year 07
11.08.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.08.2009
AT09.11.2016
BE09.11.2016
CY09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
MC09.11.2016
MK09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
TR09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
IE05.08.2017
LU05.08.2017
MT05.08.2017
[2020/15]
Former [2019/51]HU05.08.2009
AT09.11.2016
BE09.11.2016
CY09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
MC09.11.2016
MK09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
IE05.08.2017
LU05.08.2017
MT05.08.2017
Former [2019/46]HU05.08.2009
AT09.11.2016
BE09.11.2016
CY09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
MC09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
IE05.08.2017
LU05.08.2017
MT05.08.2017
Former [2019/31]HU05.08.2009
AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
MC09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
IE05.08.2017
LU05.08.2017
MT05.08.2017
Former [2018/43]AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
MC09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
IE05.08.2017
LU05.08.2017
MT05.08.2017
Former [2018/34]AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
MC09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
IE05.08.2017
LU05.08.2017
Former [2018/18]AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
MC09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/52]AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SI09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/38]AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SK09.11.2016
SM09.11.2016
BG09.02.2017
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/37]AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
IT09.11.2016
LT09.11.2016
LV09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SK09.11.2016
SM09.11.2016
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/36]AT09.11.2016
BE09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
LT09.11.2016
LV09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
SK09.11.2016
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/35]AT09.11.2016
CZ09.11.2016
DK09.11.2016
EE09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
LT09.11.2016
LV09.11.2016
NL09.11.2016
PL09.11.2016
RO09.11.2016
SE09.11.2016
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/33]AT09.11.2016
DK09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
LT09.11.2016
LV09.11.2016
NL09.11.2016
PL09.11.2016
SE09.11.2016
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/26]AT09.11.2016
ES09.11.2016
FI09.11.2016
HR09.11.2016
LT09.11.2016
LV09.11.2016
NL09.11.2016
PL09.11.2016
SE09.11.2016
NO09.02.2017
GR10.02.2017
IS09.03.2017
PT09.03.2017
Former [2017/12]LV09.11.2016
Documents cited:Search[XI]US5527940  (KAWABE NORIO [JP], et al) [X] 1-3,6,7 * column 9; examples 2, 3; compounds 12, 13 * * column 27 - column 28; examples 34, 35 * [I] 4,5,8-13;
 [I]EP1057488  (TORAY INDUSTRIES [JP]) [I] 1-13 * claims 6, 8 *
International search[A]WO0038693  (TORAY INDUSTRIES [JP], et al);
 [A]WO0108690  (TORAY INDUSTRIES [JP], et al);
 [A]WO0117562  (YAMANOUCHI PHARMA CO LTD [JP], et al);
 [A]WO9419359  (TORAY INDUSTRIES [JP]);
 [A]WO9305052  (TORAY INDUSTRIES [JP])
 [A]  - IWASE M ET AL., "A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles", JOURNAL OF ORTHOPAEDIC RESEARCH, (2002), vol. 20, pages 499 - 505, XP008147712

DOI:   http://dx.doi.org/10.1016/S0736-0266(01)00155-3
 [A]  - KANGJUNG KIM, "Osteolysis no Yakubutsugakuteki Yobo to Chiryo", JOURNAL OF JAPANESE SOCIETY FOR BIOMATERIALS, (2005), vol. 23, no. 6, pages 390 - 395, XP008148008
Examination   - SHIBUTANI T ET AL, "Local application of bisphosphonate stimulates alveolar bone formation following tooth extraction", JOURNAL OF BONE AND MINERAL RESEARCH, & TWENTY-SECOND ANNUAL MEETING OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH; TORONTO, ONTARIO, CANADA; SEPTEMBER 22-26, 2000, (200009), vol. 15, no. Suppl. 1, ISSN 0884-0431, page S339, XP055091863

DOI:   http://dx.doi.org/10.1002/jbmr.5650150102
    - BOBYN J D ET AL, "Zoledronic acid causes enhancement of bone growth into porous implants.", THE JOURNAL OF BONE AND JOINT SURGERY. BRITISH VOLUME MAR 2005, (200503), vol. 87, no. 3, ISSN 0301-620X, pages 416 - 420, XP009174868

DOI:   http://dx.doi.org/10.1302/0301-620X.87B3.14665
    - KAJIWARA H ET AL, "The bisphosphonate pamidronate on the surface of titanium stimulates bone formation around tibial implants in rats", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 26, no. 6, ISSN 0142-9612, (20050201), pages 581 - 587, (20050201), XP027767834
    - TANZER MICHAEL ET AL, "The Otto Aufranc Award: bone augmentation around and within porous implants by local bisphosphonate elution.", CLINICAL ORTHOPAEDICS AND RELATED RESEARCH DEC 2005, (200512), vol. 441, ISSN 0009-921X, pages 30 - 39, XP009174866

DOI:   http://dx.doi.org/10.1097/01.blo.0000194728.62996.2d
by applicantJP8026048B
 JP3626500B
 JP2546067B
 WO0105403
 JP3566984B
    - TAKAOKA Y, NAGAI H, MORI H, TANAHASHI M, "The effect of MPMBP on experimental arthritis in mice", BIOL PHARMACO BULL, (1997), vol. 20, pages 1147 - 50
    - TANAHASHI M, FUNABA Y, ITOH M, KAWABE N, NAKADATE-MATSUSHIMA T, "Inhibitory effect of MPMBP on rat adjuvant arthritis", PHARMACOLOGY, (1998), vol. 56, pages 242 - 251
    - TANAHASHI M, KOIKE J, KAWABE N, NAKADATE-MATSUSHIMA T, "Inhibitory effect of TRL-530 on inflammatory cytokines in bone marrow of rats with adjuvant arthritis", PHARMACOLOGY, (1998), vol. 56, pages 237 - 241
    - IWASE M, KIM KJ, KOBAYASHI Y, ITOH M, ITOH T, "A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles", J ORTHOP RES, (2002), vol. 20, pages 499 - 505
    - TANAHASHI M, FUNABA Y, TATEISHI A, KAWABE N, NAKADATE-MATSUSHIMA T, "MPMBP inhibits accumulation of superoxide anions derived from human polymorphonuclear leukocytes and bone resorption induced by activated osteoclasts", PHARMACOLOGY, (1998), vol. 56, pages 125 - 130
    - SIKDER MN, ITOH M, IWATSUKI N, SHINODA H, "Inhibitory effect of a novel bisphosphonate, MPMBP, on dental calculus formation in rats", J PERIODONTOL, (2004), vol. 75, pages 537 - 45
    - SHINODA H, TAKEYAMA S, SUZUKI K, MURAKAMI S, YAMADA S, "A novel bisphosphonate for the treatment of periodontitis", J PHARMACOL SCI, (2008), vol. 106, pages 555 - 558
    - FLEISCH H, "Experimental basis for the use of bisphosphonates in Paget's disease of bone", CLIN ORTHOP RELAT RES, (1987), vol. 217, pages 72 - 78
    - LOWRY ET AL., J BIOCHEM, (1954), vol. 207, pages 19 - 37
    - FELIX, FLEISCH, BIOCHEM J, (1979), vol. 183, pages 73 - 81
    - IGARASHI ET AL., PROSTAGLANDINS, LEUKOTRIENS, AND ESSENTIAL FATTY ACIDS, (1997), vol. 56, pages 12 - 125
    - STEM, KRIEGER, CALCIF TISSUE INT, (1983), vol. 35, pages 172 - 17
    - SUZUKI, TAKEYAMA ET AL., J HISTOCHEM CYTOCHEM, (2005), vol. 53, pages 1525 - 1537
    - TSUCHIMOTO, AZUMA ET AL., JPN J PHARMACOL, (1994), vol. 66, pages 25 - 33
    - DUQUE, RIVAS, J BONE MINER RES, (2007), vol. 22, pages 1603 - 1611
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.